Azacitidine combined with the selective FLT3 kinase inhibitor crenolanib disrupts stromal protection and inhibits expansion of residual leukemia-initiating cells in <i>FLT3</i>-ITD AML with concurrent epigenetic mutations

Benutzer: Gast

Titel:: Azacitidine combined with the selective FLT3 kinase inhibitor crenolanib disrupts stromal protection and inhibits expansion of residual leukemia-initiating cells in FLT3-ITD AML with concurrent epigenetic mutations
Dokumenttyp:: Zeitschriftenaufsatz
Autor(en):: Garz, Anne-Kathrin; Wolf, Saskia; Grath, Sonja; Gaidzik, Verena; Habringer, Stefan; Vick, Binje; Rudelius, Martina; Ziegenhain, Christoph; Herold, Sylvia; Weickert, Marie-Theresa; Smets, Martha; Peschel, Christian; Oostendorp, Robert A.J.; Bultmann, Sebastian; Jeremias, Irmela; Thiede, Christian; Döhner, Konstanze; Keller, Ulrich; Götze, Katharina S.
Zeitschriftentitel:: Oncotarget
Jahr:: 2017
Band / Volume:: 8
Heft / Issue:: 65
Volltext / DOI:: doi:10.18632/oncotarget.21877
Verlag / Institution:: Impact Journals, LLC
E-ISSN:: 1949-2553
Publikationsdatum:: 19.10.2017
BibTeX

Vorkommen:

Azacitidine combined with the selective FLT3 kinase inhibitor crenolanib disrupts stromal protection and inhibits expansion of residual leukemia-initiating cells in FLT3-ITD AML with concurrent epigenetic mutations